MA57599B1 - Semaglutide pour le traitement de la démence d'alzheimer - Google Patents

Semaglutide pour le traitement de la démence d'alzheimer

Info

Publication number
MA57599B1
MA57599B1 MA57599A MA57599A MA57599B1 MA 57599 B1 MA57599 B1 MA 57599B1 MA 57599 A MA57599 A MA 57599A MA 57599 A MA57599 A MA 57599A MA 57599 B1 MA57599 B1 MA 57599B1
Authority
MA
Morocco
Prior art keywords
semaglutide
dementia
alzheimer
treatment
glp
Prior art date
Application number
MA57599A
Other languages
English (en)
French (fr)
Inventor
Anna SECHER
Sarah FRIEDRICH
Charlotte Christine Thim HANSEN
Lotte Bjerre Knudsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA57599(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of MA57599B1 publication Critical patent/MA57599B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA57599A 2019-11-06 2020-11-05 Semaglutide pour le traitement de la démence d'alzheimer MA57599B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP20186623 2020-07-20
EP20803489.2A EP4054620B1 (en) 2019-11-06 2020-11-05 Semaglutide in the treatment of alzheimer's dementia
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Publications (1)

Publication Number Publication Date
MA57599B1 true MA57599B1 (fr) 2024-06-28

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57599A MA57599B1 (fr) 2019-11-06 2020-11-05 Semaglutide pour le traitement de la démence d'alzheimer

Country Status (19)

Country Link
US (4) US20220280612A1 (cg-RX-API-DMAC7.html)
EP (2) EP4054620B1 (cg-RX-API-DMAC7.html)
JP (2) JP7670698B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110731A (cg-RX-API-DMAC7.html)
CN (1) CN114728042A (cg-RX-API-DMAC7.html)
AU (1) AU2020377469A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007721A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154744A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984177T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241052T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067514T2 (cg-RX-API-DMAC7.html)
IL (1) IL291876A (cg-RX-API-DMAC7.html)
MA (1) MA57599B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022004779A (cg-RX-API-DMAC7.html)
PH (1) PH12022550842A1 (cg-RX-API-DMAC7.html)
PL (1) PL4054620T3 (cg-RX-API-DMAC7.html)
RS (1) RS65780B1 (cg-RX-API-DMAC7.html)
TW (2) TWI890704B (cg-RX-API-DMAC7.html)
WO (1) WO2021089678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4262873A4 (en) * 2020-12-16 2024-12-11 The Chinese University of Hong Kong A method for reversing aging brain functional decline
CN118510545A (zh) 2021-12-02 2024-08-16 哥本哈根大学 用于治疗神经退行性疾病的肽-药物缀合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
WO2026096637A1 (en) * 2024-10-30 2026-05-07 Tiziana Life Sciences Plc Glp-1 agonists and foralumab combination therapies
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
US8756102B2 (en) * 2009-11-06 2014-06-17 Edatanetworks Inc. Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
AU2016379403B2 (en) * 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Also Published As

Publication number Publication date
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (en) 2021-05-14
EP4054620A1 (en) 2022-09-14
EP4414031A3 (en) 2025-02-05
TW202519256A (zh) 2025-05-16
ES2984177T3 (es) 2024-10-29
MX2022004779A (es) 2022-06-14
TWI923289B (zh) 2026-04-21
JP2023500032A (ja) 2023-01-04
IL291876A (en) 2022-06-01
EP4054620C0 (en) 2024-05-29
BR112022007721A2 (pt) 2022-07-12
KR20220110731A (ko) 2022-08-09
PL4054620T3 (pl) 2024-10-14
CA3154744A1 (en) 2021-05-14
EP4414031A2 (en) 2024-08-14
TW202118509A (zh) 2021-05-16
US20220280612A1 (en) 2022-09-08
EP4054620B1 (en) 2024-05-29
US12539326B2 (en) 2026-02-03
US20240207364A1 (en) 2024-06-27
TWI890704B (zh) 2025-07-21
HRP20241052T1 (hr) 2024-11-08
US20250099549A1 (en) 2025-03-27
JP7670698B2 (ja) 2025-04-30
PH12022550842A1 (en) 2023-10-09
CN114728042A (zh) 2022-07-08
US20230302094A1 (en) 2023-09-28
AU2020377469A1 (en) 2022-04-28
HUE067514T2 (hu) 2024-10-28
JP2025027130A (ja) 2025-02-26

Similar Documents

Publication Publication Date Title
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
Spudich Immune activation in the central nervous system throughout the course of HIV infection
Boada et al. Neuropsychological, neuropsychiatric, and quality‐of‐life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA45543B1 (fr) Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations
MA56226B1 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
PH12022550842A1 (en) Glp-1 receptor agonists in dementia
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA49673B1 (fr) Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EP3810142A4 (en) ANTIRETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EA202190569A1 (ru) Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
EA202190755A1 (ru) Агенты для терапии и диагностики рака
Karino et al. Inhibitor of NF‐κB kinase subunit ε contributes to neuropsychiatric manifestations in lupus‐prone mice through microglial activation
EP3740761A4 (en) ACCOMPANYING DIAGNOSTICS FOR NSAIDS AND DONEPEZIL FOR THE TREATMENT OF SPECIFIC SUBPOPULATIONS OF PATIENTS WITH ALZHEIMER'S MORBUS
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3443984A4 (en) PHARMACEUTICAL COMPOSITION FOR REDUCING THE SYMPTOMS AND THE SERIOUS DEGREE OF RESPIRATORY INFECTION BY human metapneumovirus (hMPV) WITH AT LEAST ONE FUNCTION OF TSLP- AND / OR TSLPR- AND / OR OX40L- AND / OR CD177-MOLECULE neutralizing agent AND PHARMACEUTICAL ACCEPTABLE ALTERNATIVE FUEL AND USE THEREOF
MA32299B1 (fr) Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
Huang et al. Rosiglitazone suppresses HIV-1 Tat-induced vascular inflammation via Akt signaling